This Government Contract opportunity from Department Of Health And Human Services was posted on June 11, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

iNDI FA13.1J Cell Lines Expansion and Distribution for the iPSC Neurodegenerative Disease Initiative (iNDI) Project

Closed

NIH-NOI-26-PCA-NIA-01205Federal

Submission Closed06/23/2026, 03:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

SLED

81627Y0875-Purchase of Raboravel V-RG Vaccines

Solicitation # 81627Y0875

The New York City Department of Health and Mental Hygiene (DOHMH) is seeking to establish a six-year agreement with Boehringer Ingelheim Animal Health USA Inc. for the procurement of RABORAL V-RG coated sachet baits. This licensed oral rabies vaccine is used in the city's baiting program to immunize raccoons and reduce the transmission of rabies to other animals and humans. DOHMH has identified Boehringer Ingelheim as the sole source provider, as they are the only manufacturer and distributor of USDA-approved oral rabies vaccine baits for raccoons and coyotes in the United States. Under the terms of the agreement, the vendor will provide up to 75,600 individual baits per contract year, sold in quantities of 300. Deliveries must be packed with cold packs and shipped to the NYC Public Health Laboratory at 455 First Avenue, New York, NY 10016, with each shipment accompanied by an invoice. Purchase quantities and delivery schedules will be determined by operational needs, including annual fall baiting campaigns, targeted spring baiting, or emergency responses to rabies outbreaks. Interested firms may submit an Expression of Interest via RFI-EPIN 81627Y0875 by November 9, 2026, at 2:00 PM.

Department Of Health And Mental Hygiene

POSTED

DEADLINE

Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)

Solicitation # 12639527R0001

Solicitation 12639527R0001 is a request for proposal issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an unrestricted, IDIQ contract focused on Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC). The scope of work includes the purchase and storage of VAC, the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract features a ceiling price of 800 million dollars and a long-term performance horizon, consisting of five one-year ordering periods for VAC and direct purchases starting December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The contractor is required to produce VAC with a minimum capacity of 1.0 million doses and maintain storage on their premises under strict quality control and temperature monitoring standards. Due to the nature of the material, live FMDV is classified as a Tier 1 Select Agent, requiring specific authorization from the CDC/APHIS and adherence to rigorous shipping and security restrictions. Award will be based on the most advantageous offer, evaluating technical capability, past performance, and price, with technical and past performance factors weighted equally. Proposals must be submitted electronically in four separate volumes by November 10, 2026.

POSTED

DEADLINE

QPL Polysulfide Sealing Compound Supplier (NSN 8030014796036)This subcontract involves the supply of low-density polysulfide synthetic rubber sealing compound, identified by NSN 8030014796036, for prime contractors under Defense Logistics Agency supply contracts. The material must be gray, include separate catalysts, and strictly conform to SAE Aerospace Material Specification AMS 3281E, Type 1, Class B-1/2. The successful provider is required to maintain QPL-approved manufacturing standards and hold HazMat shipping certifications in accordance with IP025 and 29 CFR 1910.1200. The scope of work requires the delivery of six kits of the sealing compound to Hill AFB in Utah. This procurement falls under NAICS code 325414 and is managed by the Department of Defense. Interested parties must adhere to the specified response deadline of November 2, 2026.

Defense Logistics Agency

POSTED

DEADLINE

Custom Homing Peptide Synthesis and AAV Capsid ModificationThis subcontract for the Department of Veterans Affairs, specifically supporting the Harry S Truman Memorial Veterans Hospital, involves the synthesis of targeting peptides and genetic engineering services. The scope of work includes designing homing peptides, modifying AAV capsid genomes for peptide display, and producing modified viral vector prototypes. These activities are to be conducted using molecular cloning tools and DNA/RNA synthesis platforms within BSL-2 facilities. The selected provider must hold BSL-2 certification to deliver the required modified AAV vector constructs and synthesized peptide sequences. Performance of the contract will take place in Columbia, Missouri, under NAICS code 325414. The solicitation was posted on October 21, 2026, with a response deadline of November 4, 2026.

POSTED

DEADLINE

Brand Name - Dectomax (Doramectin) 500mL Injectable Solution

Solicitation # 12639527Q0009

Solicitation 12639527Q0009 is a combined synopsis and request for quotation issued by the Department of Agriculture for the procurement of 2,400 bottles of Dectomax (Doramectin) 500mL Injectable Solution. This firm-fixed-price acquisition is a total small business set-aside under NAICS code 325414 and is intended to support the USDA Cattle Fever Tick Eradication Program in Texas. The required items must be new and the exact brand name specified from Zoetis Inc., as alternate or substitute products are deemed technically unacceptable. All deliverables must be shipped F.O.B. destination to Laredo, Texas, within 30 days of the contract award. Award will be made based on best value, specifically to the lowest priced, technically acceptable offer with an acceptable or neutral past performance rating. To be considered technically acceptable, offerors must provide sufficient documentation, such as manufacturer quotes or datasheets, to verify the product and ensure a clear, auditable paper trail of traceability back to the original equipment manufacturer. Additionally, contractors must furnish a Certificate of Conformance per FAR 52.246-15. Quotations must remain firm for 90 calendar days, and the deadline for submission is October 30, 2026.

POSTED

DEADLINE

Solicitation # SPE2DP-26-R-0001

Solicitation SPE2DP-26-R-0001 is a sole source, firm-fixed price, indefinite delivery, indefinite quantity contract issued by the Defense Logistics Agency for the procurement of Japanese Encephalitis Virus Vaccine, Purified, Inactivated, in single-dose prefilled syringes. The contract has an eighteen month base term with estimated quantities ranging from a minimum of 277,760 to a maximum of 394,240 units. All products must be FDA approved, serialized according to the Drug Supply Chain Security Act, and manufactured in accordance with Medical Procurement Item Description Number 5. Deliveries are designated as FOB Destination to DLA Distribution Susquehanna in New Cumberland, Pennsylvania, and must be completed within 120 days after the date of order. The successful offeror must demonstrate FDA approval or provide a manufacturer commitment letter ensuring supply availability and fixed pricing for the life of the contract. Proposals must be submitted electronically via the DLA Internet Bid Board System by November 6, 2026. Strict adherence to Medical Marking Standard No. 1D is required, specifically regarding cold chain storage between 2 and 8 degrees Celsius and detailed waterproof marking for exterior containers. Contract administration, including payment requests and receiving reports, will be managed through the Wide Area Workflow system. Award will be based on the most advantageous offer considering price, FDA approval, and agreement to all solicitation terms.

Defense Logistics Agency

POSTED

DEADLINE

VAC to Finished Vaccine ConversionThis subcontract involves the conversion of Government-owned Vaccine Antigen Concentrate into final-use Foot and Mouth Disease vaccine doses for prime contractors supporting USDA APHIS projects. The scope of work includes formulating the concentrate into a usable vaccine, performing filling and packaging within cleanroom facilities, and conducting essential final potency and efficacy testing. The project is managed under the Department of Agriculture and will be performed in Ames, Iowa. To be eligible, the contractor must hold a USDA Veterinary Biological Product License. The solicitation was posted on October 1, 2026, with a response deadline of November 10, 2026, falling under NAICS code 325414.

POSTED

DEADLINE

FMD Vaccine Antigen Concentrate (VAC) ProductionThis subcontract for the Department of Agriculture involves the production of Foot and Mouth Disease Vaccine Antigen Concentrates for prime contractors on USDA APHIS projects. The scope of work includes the purification and concentration of VAC serials, which are produced by engineering Master Seed Viruses or utilizing field strains in accordance with 9 CFR Parts 113 and 114. To qualify, the provider must possess a USDA Veterinary Biological Product License and provide propagation cell line data approved by the Center for Veterinary Biologics. The final deliverables are purified and concentrated FMD VAC serials, with performance taking place in Ames, Iowa. The response deadline for this opportunity is November 10, 2026.

POSTED

DEADLINE

Antithrombin III Procurement

Solicitation # CBP-CON-00260

The National Blood Authority is seeking tenders for the procurement of an Antithrombin III product under solicitation number CBP-CON-00260. While the agency currently maintains supply arrangements for Thrombotrol through the National Fractionation Agreement for Australia, this request for tender opens the process for the provision of these essential medical supplies. Interested parties must submit their responses by the deadline of November 20, 2026. All inquiries and submissions should be directed to the CBP Procurement Team via the provided contact email. Further detailed specifications and requirements are contained within the official request for tender documentation.

National Blood Authority

POSTED

DEADLINE

Proteomics and Protein Expression AnalysisThe Proteomics and Protein Expression Analysis subcontract supports National Institutes of Health projects focused on identifying biomarkers related to substance exposure and brain development. The selected provider will perform protein identification and quantification for prime contractors using a variety of high-sensitivity methods, including mass spectrometry, ELISA, Western blotting, and protein-protein interaction assays via LC-MS/MS. To ensure the integrity of the results, the performing laboratory must adhere to ISO/IEC 17025 quality standards. The primary deliverables for this engagement consist of detailed quantitative biomarker reports and comprehensive protein expression profiles. This effort falls under NAICS code 325414 and is managed through the Department of Health and Human Services.

National Institutes Of Health

POSTED

DEADLINE

Medical Diagnostic Test Kit SupplyThe Defense Logistics Agency under the Department of Defense has issued a subcontract for the supply of 100 E. coli detection test kits. These diagnostic kits must strictly adhere to FDA regulations, specific shelf-life requirements, and Department of Defense medical packaging standards to ensure quality and viability. Classified under NAICS code 325414, this procurement focuses on the delivery of specialized medical diagnostic tools. The contract was posted on August 11, 2026, and is managed through the DLA's acquisition systems to support military medical readiness.

Defense Logistics Agency

POSTED

DEADLINE

Medical Supply Procurement – Petrolatum GauzeThis subcontract with the Defense Logistics Agency under the Department of Defense involves the manufacture or supply of 27 units of petrolatum gauze, identified by NSN 6510-01-112-6414. The procurement falls under NAICS code 325414 and requires all units to meet strict military medical standards. Key delivery requirements include a minimum shelf life of 36 months, with a mandate that the time elapsed from manufacture to delivery does not exceed five months. The contract was posted on August 10, 2026.

Defense Logistics Agency

POSTED

3 months ago

DEADLINE

N/A

AI Contract Overview

The National Institute on Aging, through its Center for Alzheimer’s Disease and Related Dementias, intends to award a sole source firm-fixed-price contract to The Jackson Laboratory for the expansion, quality control, curation, biobanking, and public distribution of up to 936 isogenic induced pluripotent stem cell lines supporting the iPSC Neurodegenerative Disease Initiative. The requirement includes 486 female SNV lines and 450 additional lines derived from 25 high-priority SNV trios across six engineered cell lines, all developed using CRISPR-Cas12a technology based on gene variants provided by the government. The contractor must expand and validate each line according to strict iNDI protocols, which mandate post-thaw viability exceeding 80% for manual expansion or 50% confluency within 10 days for automated expansion, negative sterility results across bacterial, fungal, viral, and mycoplasma panels, confirmation of intended genetic edits via PCR and Sanger sequencing, absence of reprogramming vectors, normal karyotype via SNP-based digital karyotyping, and pluripotency marker expression confirmed by RNA sequencing. Each cell line must be accompanied by comprehensive quality control documentation and curated product web content, with all lines made available for public purchase through a contractor-hosted platform that maintains continuity with existing iNDI resources. The contract includes a base year from September 1, 2026, through August 31, 2027, and three optional one-year extensions through August 31, 2030, with performance to occur exclusively at The Jackson Laboratory’s facility in Bar Harbor, Maine. The authority for sole source acquisition is based on 41 U.S.C. 1901 and FAR 6.302-1, as The Jackson Laboratory is the only known entity capable of delivering the required cell lines and infrastructure, having previously executed similar iNDI tasks and maintaining the existing distribution platform. The government has issued a notice of intent and invites capability statements from other responsible sources by June 23, 2026, to evaluate potential for competition, though no competitive solicitation is currently planned. Responses must include company identification, UEI and CAGE codes, business size and socioeconomic status, technical point of contact details, a narrative demonstrating capability to meet all technical requirements, and relevant past performance evidence, all submitted electronically to the designated contracting officers.

General Info

Sole source contract to Jackson Laboratory for expanding and distributing 936 Alzheimer’s iPSC lines.

Agency

Department Of Health And Human Services → National Institutes Of Health Olao

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Bar Harbor, ME, 04609, USA

Set-Aside

NONE

Documents

SOW for iNDI FA13.1J Cell Lines Expansion and Distribution

sow

High

NIH Notice of Intent to Sole Source Contract NIH-NOI-26-PCA-NIA-01205

special-notice

Low

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJun 11

special-notice

Response DeadlineJun 23

Deadline has passed

Submission Closed

06/23/2026, 03:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts2 people available

OfficeBETHESDA, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Office AddressBETHESDA, MD, 20892, USA

Contacts

Linda Smith

contact@example.gov

Danielle Tines

contact@example.gov

Full Description

SPECIAL NOTICE
NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT

Agency: Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute on Aging (NIA)
Office: Center for Alzheimer’s Disease and Related Dementias (CARD)
Notice Type: Special Notice
Notice Number: NIH-NOI-26-PCA-NIA-01205

Title: Notice of Intent to Sole Source – iNDI FA13.1J Cell Lines Expansion and Distribution for the iPSC Neurodegenerative Disease Initiative (iNDI) Project
NAICS Code: 325414 – Biological Product (except Diagnostic) Manufacturing
PSC: 6550 – In Vitro Diagnostic Substances, Reagents, Test Kits and Sets

Description

This is a notice of intent to award a sole source contract and is not a request for competitive quotations, proposals, or bids. The National Institute on Aging (NIA), Center for Alzheimer’s Disease and Related Dementias (CARD), intends to negotiate and award a firm-fixed-price contract to:

The Jackson Laboratory
600 Main Street
Bar Harbor, ME 04609
UEI: XR6LMXNKDJJ1

for iNDI FA13.1J Cell Lines Expansion and Distribution for the iPSC Neurodegenerative Disease Initiative (iNDI) Project.

The anticipated contract will provide for the expansion, quality control, curation, biobanking, and distribution of up to 936 isogenic Alzheimer’s disease and related dementias (ADRD) induced pluripotent stem cell (iPSC) lines in support of the iPSC Neurodegenerative Disease Initiative (iNDI). The requirement includes:

FA13.1J female SNV lines totaling 486 iPSC lines;
25 high-priority SNV trios across six additional iPSC lines totaling 450 iPSC lines;
expansion and quality control in accordance with current iNDI protocols;
product and web content creation for each iPSC line; and
public distribution of cell lines through an established contractor-hosted website/platform.

The statutory authority for this acquisition is 41 U.S.C. 1901, as implemented by FAR 13.501(a)(1)(ii), based on the circumstances described in FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.

The Government’s market research included review of the prior sources sought notice posted on SAM.gov under Notice ID 75N95025Q00209-SBSS, review of prior NIH awards for similar iNDI requirements, and review of commercially available information regarding potential sources. Based on that market research, The Jackson Laboratory is the only known source capable of providing the specific iNDI FA13.1J iPSC cell lines and associated expansion, quality control, curation, and distribution services required for this acquisition. The Jackson Laboratory also maintains the existing iNDI distribution infrastructure and has successfully performed prior related iNDI requirements for NIH.

Period of Performance

Base Year: September 1, 2026 – August 31, 2027
Option Year 1: September 1, 2027 – August 31, 2028
Option Year 2: September 1, 2028 – August 31, 2029
Option Year 3: September 1, 2029 – August 31, 2030

Place of Performance

The principal place of performance is the contractor’s facility.

Responses

This notice is not a solicitation. However, any responsible source that believes it can satisfy the Government’s requirement may submit a capability statement for the Government’s consideration. Capability statements shall clearly demonstrate the ability to provide:

the specific iNDI FA13.1J cell lines and associated iNDI lines required under this acquisition;
expansion and quality control in accordance with current iNDI protocols;
product and web content creation for each iPSC line;
public distribution through an established contractor-hosted platform; and
continuity sufficient to preserve comparability with existing iNDI resources and prior work.

Responses shall include, at a minimum:

Company name
UEI and CAGE Code, if applicable
Business size and socioeconomic status
Technical point of contact, including name, title, telephone number, and email address
Narrative capability statement addressing the requirements above
Relevant past performance information for similar efforts

Responses must be submitted electronically to the point(s) of contact below no later than June 23, 2026, 11:00 am EST. Responses received after the stated deadline may not be considered.

The Government will review all timely responses solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. The Government will not be responsible for any costs incurred by respondents in preparing or submitting a response.

Point(s) of Contact

Primary Point of Contact: Linda Smith, Contracting Officer, contact@example.gov

Secondary Point of Contact: Danielle Tines, Procurement Technician, contact@example.gov